Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies I
Ontology highlight
ABSTRACT: IFNγ neutralization by the clinically approved monoclonal antibody emapalumab mitigates severe toxicity related to CAR-T therapy Emapalumab does not impair CAR.CD19 T-cell activation signaling
ORGANISM(S): Homo sapiens
PROVIDER: GSE228921 | GEO | 2023/05/04
REPOSITORIES: GEO
ACCESS DATA